Results 101 to 110 of about 3,522 (243)
Considerations for the Treatment Strategy of Relapse After Tofacitinib Therapy in Alopecia Areata
Journal of Cosmetic Dermatology, Volume 24, Issue 7, July 2025.ABSTRACT Background Alopecia areata (AA) is an autoimmune disorder mediated by T cells, resulting in hair loss on the scalp, eyebrows, and body. Conventional treatments for AA often exhibit high recurrence rates and various side effects. Recently, Janus kinase (JAK) inhibitors have emerged as promising therapeutic options for managing AA and several ...
Longyan Yao +3 more
wiley +1 more source
Alopecia Areata and Systemic Lupus Erythematosus: Insights From a Nationwide Case–Control Study
International Journal of Dermatology, EarlyView.
Yonit Wohl +4 more
wiley +1 more source
Pediatric Dermatology, Volume 42, Issue 4, Page 742-746, July/August 2025.ABSTRACT Background Alopecia areata (AA) is an autoimmune disease characterized by hair loss that can negatively impact quality of life. AA has a significant pediatric prevalence; however, no systemic treatments are approved for AA in patients aged < 12 years. Ritlecitinib, a JAK3/TEC family kinase inhibitor, is approved to treat adults and adolescents
Mercedes E. Gonzalez +7 more
wiley +1 more source
Comprehensive Safety Exposure‐Response Analysis to Support Ritlecitinib Dose Selection
CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 6, Page 1108-1118, June 2025.ABSTRACT Ritlecitinib is a kinase inhibitor drug recently approved for the treatment of alopecia areata (AA) in both adults and adolescents based on a single, combined Phase 2b/3 study. Various QD doses with and without a loading dose have been evaluated in the pivotal Phase 2b/3 study.
Yeamin Huh +5 more
wiley +1 more source
Alimentary Pharmacology &Therapeutics, Volume 61, Issue 12, Page 1854-1871, June 2025.Evidence for medical therapies targeting joint, skin and eye EIMs in IBD is heterogeneous and of low certainty. Multidisciplinary care and development of standardised, more appropriate outcome measures are essential to improve evaluation and guide future research. ABSTRACT Background Extraintestinal manifestations (EIMs) occur commonly in patients with
Olga M. Nardone +9 more
wiley +1 more source
SALT score distribution with ritlecitinib treatment up to 24 months in alopecia areata
Journal of the European Academy of Dermatology and Venereology, EarlyView.
Ziad Reguiai +8 more
wiley +1 more source
International Journal of Dermatology, Volume 64, Issue 6, Page 1013-1020, June 2025.ABSTRACT Despite increasing attention regarding skin diseases in individuals with skin of color (SoC), there remains a significant gap in understanding and identifying inflammatory nail disorders in this population. This systematic review aims to synthesize the clinical and onychoscopic features of inflammatory nail disorders in patients with SoC ...
Lea Tordjman +3 more
wiley +1 more source
Molecular signatures define alopecia areata subtypes and transcriptional biomarkers
EBioMedicine, 2016 Alopecia areata (AA) is an autoimmune disease typified by nonscarring hair loss with a variable clinical course. In this study, we conducted whole genome gene expression analysis of 96 human scalp skin biopsy specimens from AA or normal control subjects.
Ali Jabbari +9 more
doaj +1 more source
Serum Interleukin-4 and Total Immunoglobulin E in Nonatopic Alopecia Areata Patients and HLA-DRB1 Typing [PDF]
, 2010 Background. Interleukin-4 (IL-4), a Th2 cytokine, can stimulate immunoglobulin E (IgE) transcription. No previous studies evaluated the genetic mechanisms in nonatopic AA patients with elevated serum IgE. Objective.
Attia, Enas A. S. +2 more
core +3 more sources